БриџБио Фарма
stock was soaring after the biopharmaceutical company reported positive results in a Phase two clinical trial for an experimental treatment for achondroplasia, the most common type of short-limbed dwarfism.
On Monday, BridgeBio (ticker: BBIO) said in a news release that its experimental drug Infigratinib showed an annualized improvement of 3.03 centimeters in so-called height velocity, or gains in height, in a study including 10 children.
Source: https://www.barrons.com/articles/bridgebio-stock-dwarfism-drug-biomarin-40cc3e70?siteid=yhoof2&yptr=yahoo